Ketek's new labeling approved by FDA

Share this article:
Ketek (telithromycin), Sanofi-Aventis' antibiotic, has had new labeling approved by the FDA, including a bolded warning and additional information on liver toxicity and failure, as well as revised recommendations for use in patients with myasthenia gravis. The agency says Ketek's benefits outweigh its potential risks when used according to the labeling.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.